Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL485921 | 0.97 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL27747511 | 0.82 | DGAT1 (0.50) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL6687359 | 0.82 | DGAT1 (0.50) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL1061233 | 0.80 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| Hydrochloric Acid SCHEMBL16632764 | 0.80 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL10892362 | 0.80 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL1926432 | 0.79 | DGAT1 (0.38) | DGAT1USP2SMN1; SMN2ELANE | |
| Benzoic Acid SCHEMBL28735573 | 0.78 | TSHR (0.50) | BCHEELANETDP1ALDH1A1 | |
| SCHEMBL13063668 | 0.78 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL21058313 | 0.78 | DGAT1 (0.46) | DGAT1SMN1; SMN2CA1CA2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034105-B1 | POLYMORPH FORM OF (R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | GALIMEDIX THERAPEUTICS INC (US) | 2024-07-31 | — | — | EP | claimed |
| US-11891455-B2 | Polymorph form of (r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2- methylpropionic acid and uses thereof | GALIMEDIX THERAPEUTICS INC | 2024-02-06 | — | — | US | claimed |
| CN-116355042-A | Fmoc-His-Aib-OH and R1 preparation method | 上海奥博生物医药股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20220389056-A1 | NOVEL POLYMORPH FORM OF (R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | GALIMEDIX THERAPEUTICS INC. (US) | 2022-12-08 | — | — | US | claimed |
| EP-4034105-A1 | NOVEL POLYMORPH FORM OF ( R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | Galimedix Therapeutics Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114466652-A | Novel polymorphic crystal forms of (R) -2- [ 2-amino-3- (indol-3-yl) propionylamino ] -2-methylpropionic acid and uses thereof | 加利梅迪克斯治疗公司 | 2022-05-10 | — | — | CN | claimed |
| WO-2021059142-A1 | NOVEL POLYMORPH FORM OF ( R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | GALIMEDIX THERAPEUTICS INC. (US) | 2021-04-01 | — | — | WO | claimed |
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | claimed |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-04-09 | — | — | US | claimed |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | claimed |
| EP-2729465-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | Vertex Pharmaceuticals Incorporated (US) | 2014-05-14 | — | — | EP | claimed |
| US-8513414-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-20 | — | — | US | claimed |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013006634-A9 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2013006634-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | WO | claimed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-0272063-B1 | MITOMYCIN DERIVATIVES | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1992-04-08 | — | — | EP | disclosed |
| US-4863935-A | Mitomycin compounds having useful anti-tumor activity | KYOWA HAKKO KOGYO K.K. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0272063-A1 | Mitomycin derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | DGAT1 2348/4885USP2 1599/4885SMN1; SMN2 4816/4885 |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | DGAT1 2348/4885USP2 1599/4885SMN1; SMN2 4816/4885 |
| US-20220389056-A1 | NOVEL POLYMORPH FORM OF (R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | CYP3A43, ABCG2, ANXA2 | DGAT1 4492/4885USP2 3639/4885SMN1; SMN2 3443/4885 |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | DGAT1 2348/4885USP2 1599/4885SMN1; SMN2 4816/4885 |
| US-11891455-B2 | Polymorph form of (r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2- methylpropionic acid and uses thereof | CYP3A43, ANXA2, ANXA3 | DGAT1 4495/4885USP2 3737/4885SMN1; SMN2 3077/4885 |
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | DGAT1 2348/4885USP2 1599/4885SMN1; SMN2 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.